Have an account? Log in to check out faster.
Once-weekly prescription weight-loss treatment
A once-weekly prescription injection that can help reduce hunger, increase fullness and support sustainable weight loss, with clinical guidance at every stage.
Mounjaro contains tirzepatide and is used once weekly. It is not suitable for everyone and is prescribed only after a clinical assessment of your health, current medicines, weight history and treatment goals.
For eligible adults of all genders
One injection each week
Clinician-selected dose progression
Side-effect and nutrition support
Ongoing weight and health reviews
Medication delivered discreetly
Quick product facts
The essentials, followed by more detail on suitability, doses, safety and what support looks like.
Active ingredient
Tirzepatide
Medicine type
GIP and GLP-1 receptor agonist
How often?
Once weekly
Pen duration
Four weekly doses
Starting strength
Usually 2.5 mg
Available strengths
2.5 mg to 15 mg
Prescription needed?
Yes
Who is it for?
Eligible adults after assessment
All strengths in one place
You do not choose a higher dose simply because it is available. Your clinician will prescribe the strength that is clinically appropriate, effective and tolerable for you.
| Strength | Typical place in pathway | Four-dose pen | LIVVE price |
|---|---|---|---|
| 2.5 mg | Usual starting dose |
One injection weekly for 4 weeks |
£205 |
| 5 mg | First maintenance-dose option |
One injection weekly for 4 weeks |
£215 |
| 7.5 mg | Further dose step if appropriate |
One injection weekly for 4 weeks |
£250 |
| 10 mg | Maintenance-dose option |
One injection weekly for 4 weeks |
£285 |
| 12.5 mg | Further dose step if appropriate |
One injection weekly for 4 weeks |
£295 |
| 15 mg | Maximum licensed weekly dose |
One injection weekly for 4 weeks |
£305 |
Higher is not automatically better. Dose increases are considered only after at least four weeks on the current dose and should depend on appetite response, weight progress, side effects, nutrition and overall health. Some people achieve good results on a lower dose.
Realistic Eligibility and clinical assessment
Mounjaro may be considered for adults living with obesity, or some adults living with overweight alongside a weight-related health condition. Private prescribing still requires an individual assessment and is not based on BMI alone.
Your current BMI, previous weight-management attempts, waist measurement and weight-related health risks are considered.
Your clinician reviews conditions such as diabetes, digestive disease, gallbladder problems, pancreatitis history and other relevant risks.
Some medicines need extra care or adjustment, including insulin, sulphonylureas and medicines affected by delayed stomach emptying.
Mounjaro is not recommended in pregnancy or while breastfeeding. Your clinician will discuss pregnancy plans and contraception where relevant.
We consider whether reduced appetite could make it harder to meet protein, fibre, fluid and micronutrient needs.
Your plan should focus on health, function and sustainable progress rather than promising a fixed amount of weight loss.
How Mounjaro works
Tirzepatide acts on GIP and GLP-1 receptors. These pathways influence appetite, food intake and blood-sugar regulation. Many people feel fuller sooner, less hungry between meals and better able to manage cravings.
Mounjaro also delays stomach emptying, particularly when treatment begins or the dose changes. This contributes to fullness but can also cause digestive side effects.
It is not a stimulant and it should not remove the need to eat. Regular, nourishing meals and adequate fluid remain important.
Dose progression
The usual starting dose is 2.5 mg once weekly. Any increase is made in 2.5 mg steps after at least four weeks, but only when clinically appropriate.
Start with 2.5 mg once weekly. Focus on injection technique, hydration, regular meals and learning how your body responds.
Your clinician considers side effects, appetite, food intake, weight change and any relevant blood-sugar readings.
You may remain on the current dose or move up by 2.5 mg. An increase is not automatic every month.
The aim is an effective, tolerable dose that supports progress without unnecessary side effects.
Using your pen
Use Mounjaro exactly as shown by your clinician, pharmacist and the pen instructions. Inject under the skin of the abdomen, thigh or upper arm, rotating the injection site.
Always follow the patient information leaflet supplied with your own pen and contact LIVVE if any step is unclear.
Use the prescribed strength only.
Take one dose each week on the same day where possible.
Use a new compatible needle for every injection.
Rotate injection sites and avoid sore, bruised or damaged skin.
Do not share your pen or needles.
Store and dispose of the pen and needles as instructed.
Never extract medicine from the pen with a syringe.
Side effects and safety
Digestive side effects are common, particularly when starting or increasing the dose. They are often manageable, but persistent or severe symptoms need clinical advice.
Common effects
Nausea, vomiting, diarrhoea, constipation, stomach pain, indigestion, tiredness, reduced appetite and injection-site redness or itching can occur.
Contact LIVVE
Speak to the team if symptoms are persistent, worsening, affecting eating or drinking, causing repeated vomiting or making normal daily activity difficult.
Seek urgent help
Get urgent medical advice for severe, persistent abdominal pain, signs of dehydration, a serious allergic reaction, or symptoms suggesting gallbladder or pancreatic inflammation.
Do not increase your dose to overcome a plateau or because you have fewer side effects. Changes must be approved by your prescriber. Severe vomiting, diarrhoea or poor fluid intake can cause dehydration and may affect kidney function.
Supporting healthy weight loss
A good programme is about more than eating as little as possible. LIVVE should help you maintain nourishing intake and build habits that can continue beyond medication.
Protein
Include a useful source at meals to support muscle maintenance and recovery.
Fibre
Increase gradually alongside fluid to support bowel health and manage constipation.
Hydration
Drink regularly, especially if nausea, vomiting or diarrhoea reduces intake.
Strength and movement
Combine regular activity with resistance exercise where appropriate for your health and ability.
Your LIVVE pathway
Whether you’re starting Mounjaro or continuing treatment, your clinician will recommend the appropriate dose based on your response, side effects and treatment history.
Tell us about your health, current medicines, weight history, previous treatment and goals.
A LIVVE clinician checks eligibility, safety, interactions and whether Mounjaro is an appropriate option.
If approved, the prescribed strength is dispensed with clear instructions and discreet delivery.
Reviews cover weight progress, appetite, nutrition, side effects, dose suitability and longer-term planning.
Where Mounjaro fits
Mounjaro is not automatically the right option for every person. Your clinician may discuss Wegovy injections or Wegovy tablets based on your health, preferences and previous treatment.
| Option | Format | How it fits |
|---|---|---|
| Mounjaro® injection | Once-weekly tirzepatide injection | Used only where clinically appropriate after assessment. |
| Wegovy® injection | Once-weekly semaglutide injection | May be discussed if it better suits your health, preferences or previous treatment. |
| Wegovy® tablets | Oral semaglutide tablet | May be discussed if it better suits your health, preferences or previous treatment. |
Start with a proper clinical assessment. LIVVE will help you understand whether treatment is appropriate, which dose to begin with and how your progress will be supported safely.
Medical disclaimer: This page is for information only and does not replace individual medical advice. Mounjaro is a prescription-only medicine supplied only after assessment and approval by an appropriate prescriber. Eligibility, prescribing, supply and dose changes are subject to clinical suitability. Always read the patient information leaflet and follow your dispensing label and clinician's instructions. Seek urgent medical help for severe or concerning symptoms.
